ASO Author Reflections: First Do No Harm-Revisiting Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Trials to Reduce the Risk of Peritoneal Metastasis

Ann Surg Oncol. 2021 Dec;28(13):9096-9097. doi: 10.1245/s10434-021-10263-z. Epub 2021 Jun 11.

Can Yurttas¹, Alfred Königsrainer^{1

2

3}, Markus W Löffler^{4

5

6

7

8}

¹ Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
² German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) Partner Site Tübingen, Tübingen, Germany.
³ Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
⁴ Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany. markus.loeffler@uni-tuebingen.de.
⁵ German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) Partner Site Tübingen, Tübingen, Germany. markus.loeffler@uni-tuebingen.de.
⁶ Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany. markus.loeffler@uni-tuebingen.de.
⁷ Interfaculty Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. markus.loeffler@uni-tuebingen.de.
⁸ Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany. markus.loeffler@uni-tuebingen.de.

No abstract available

Publication types